Tongxinluo Capsule in Ischemic Stroke Patients（TISS)

Inclusion Criteria: * Ischemic stoke within 72 after onset, confirmed by MRI or CT. * Age 35-75 years, inclusive. * Patients with the first attack or patients with stroke history(modified Rankin Scale score 0-1). * Clear signs of localization of nervous system, NIHSS score 4 to 22. * Patient or proxy has signed informed consent. Exclusion Criteria: * Hemorrhage diseases according to head CT or MRI, such as hemorrhagic stroke, epidural hematoma, intracranial hematoma, intraventricular hemorrhage, subarachnoid hemorrhage, haemorrhage after cerebral infarction. * Transient Ischemic Attack (TIA). * Severe disturbance of consciousness: 1a of NIHSS score\>1 point; Difficulty in swallowing, unable to take oral capsules; any of 5a, 5b, 6a, 6b of NIHSS score\>2 point. * Convinced of stroke caused by brain tumor, brain trauma, hemopathy, etc. * Hemorrhagic tendency patients. * Patients with endovascular treatment after the onset of stroke. * Patients with dementia, severe Parkinson's disease, mental disorders, limb dysfunction caused by other diseases or other conditions that may affect the therapeutic efficacy. * Uncontrolled hypertension (≥200 mmHg systolic or ≥110 mmHg diastolic) or hypotension (≤90 mmHg systolic or ≤60mmHg diastolic); severe hyperglycemia(blood glucose ≥400 mg/dl) or hypoglycemia( blood glucose≤50 mg/dl). * Severe hepatic insufficiency defined as transaminase values \> 2x upper limit of normal; severe renal insufficiency defined as values serum creatinine\> 1.5x upper limit of normal; cardiac dysfunction or other serious systemic disease with life expectancy ≤3 months. * Patients with concurrent malignancy or ongoing anti-tumor therapy. * Patients with history of being allergic to the trial medicine. * Pregnancy, breastfeeding or potential pregnancy. * Within three months or currently participating in another investigational study. * Any other condition that in the opinion of the investigator should preclude study participation.